Iferanserin

Iferanserin is a drug candidate that was under development for the potential treatment of hemorrhoids. It is a selective serotonin 2A receptor antagonist that was being developed by Ventrus Biosciences.

History[edit | edit source]

Ventrus Biosciences initiated the development of Iferanserin (VEN 309) with the aim of providing a novel treatment for hemorrhoids. The drug was in the Phase III stage of clinical trials when Ventrus announced in 2012 that it would not be pursuing further development due to lack of efficacy.

Mechanism of Action[edit | edit source]

Iferanserin works by selectively antagonizing the serotonin 2A receptor. Serotonin is a neurotransmitter that can cause blood vessels to contract. By blocking the action of serotonin on these receptors, Iferanserin may reduce the swelling and discomfort associated with hemorrhoids.

Clinical Trials[edit | edit source]

The efficacy of Iferanserin was evaluated in several clinical trials. In a Phase II trial, the drug showed promise in reducing the severity of hemorrhoid symptoms. However, in a subsequent Phase III trial, Iferanserin did not meet the primary endpoint of reducing the time to cessation of bleeding.

Future Development[edit | edit source]

Following the disappointing results of the Phase III trial, Ventrus Biosciences decided not to continue with the development of Iferanserin. The future of this drug candidate is currently uncertain.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.